Fredrik Ottosson - Hufvudstaden Head of the Gothenburg Business Area
| HUFAF Stock | USD 12.20 0.00 0.00% |
Executive
Mr. Fredrik Ottosson was appointed Head of the Gothenburg Business Area at Hufvudstaden AB, effective as of August 2016. He holds a MS degree and is a graduate engineer from the Royal Institute of Technology in Stockholm and he has a long and solid experience from several leading positions in the private and municipal construction and property sector in Sweden. He is currently Head of Planning and Urban Development at Halmstad Municipal Authority, where for several years he has also been a property manager and president of the municipally owned property company AB Industristaden. Prior to that, he was head of Sweco Projektledning AB in Halmstad and a project manager at Humlegarden and Hufvudstaden in Stockholm. since 2016.
| Age | 51 |
| Tenure | 9 years |
| Phone | 46 87 62 90 00 |
| Web | https://hufvudstaden.se |
Hufvudstaden Management Efficiency
The company has return on total asset (ROA) of 0.0159 % which means that it generated a profit of $0.0159 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Hufvudstaden's management efficiency ratios could be used to measure how well Hufvudstaden manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Caitlin Lowie | Ardelyx | N/A | |
| Janet MBA | Spyre Therapeutics | N/A | |
| Juliusz Komorek | Ryanair Holdings PLC | 47 | |
| John Tuite | Ryanair Holdings PLC | N/A | |
| Melissa Cooper | Spyre Therapeutics | N/A | |
| Brian Connolly | Spyre Therapeutics | N/A | |
| Gerald Underwood | Regeneron Pharmaceuticals | N/A | |
| Ryan Crowe | Regeneron Pharmaceuticals | N/A | |
| Justin LaFountaine | Spyre Therapeutics | N/A | |
| JuanCarlos MD | Valneva SE ADR | 53 | |
| Elizabeth Esq | Ardelyx | 61 | |
| Fadi MD | Alto Neuroscience, | 46 | |
| John Hurley | Ryanair Holdings PLC | 50 | |
| LLM JD | Spyre Therapeutics | 42 | |
| Jessica Powell | Alto Neuroscience, | 50 | |
| Kelly Niese | MPLX LP | 44 | |
| Vincent Dequenne | Valneva SE ADR | 58 | |
| Joseph Reilly | Ardelyx | 52 | |
| Charon Sr | Ardelyx | N/A | |
| James Myers | Spyre Therapeutics | N/A | |
| Melissa Lozner | Regeneron Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0159 |
Hufvudstaden AB Leadership Team
Elected by the shareholders, the Hufvudstaden's board of directors comprises two types of representatives: Hufvudstaden inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hufvudstaden. The board's role is to monitor Hufvudstaden's management team and ensure that shareholders' interests are well served. Hufvudstaden's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hufvudstaden's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fredrik Ottosson, Head of the Gothenburg Business Area | ||
| Bo Wikare, Head of the Stockholm City East Business Area | ||
| Anders Nygren, Head of Property Development | ||
| Asa Roslund, Acting CFO | ||
| Frida Wijkstrom, Head Area | ||
| Karl Palm, Head Devel | ||
| Ulrika Frisk, Head HR | ||
| John Lethenstrom, Head of Property Development | ||
| Mattias Karlsson, Secretary |
Hufvudstaden Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hufvudstaden a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0159 | |||
| Profit Margin | 1.00 % | |||
| Current Valuation | 3.57 B | |||
| Shares Outstanding | 194.04 M | |||
| Shares Owned By Insiders | 43.77 % | |||
| Shares Owned By Institutions | 29.08 % | |||
| Price To Earning | 7.69 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 9.87 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Hufvudstaden Pink Sheet
Hufvudstaden financial ratios help investors to determine whether Hufvudstaden Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hufvudstaden with respect to the benefits of owning Hufvudstaden security.